What Happened?

Shares of medical tech company Masimo (NASDAQ:MASI) jumped 11.6% in the afternoon session after the company reported impressive fourth-quarter 2024 results, which beat analysts' revenue and EPS expectations. Sales grew 9% year on year, fueled by broad based demand. In addition, its full-year EPS guidance outperformed Wall Street's estimates by a wide margin. Zooming out, we think this was a solid quarter.

Is now the time to buy Masimo? Access our full analysis report here, it’s free.

What The Market Is Telling Us

Masimo’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. Moves this big are rare for Masimo and indicate this news significantly impacted the market’s perception of the business.

Masimo is up 11.6% since the beginning of the year, and at $188.06 per share, has set a new 52-week high. Investors who bought $1,000 worth of Masimo’s shares 5 years ago would now be looking at an investment worth $1,123.

Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.